Kopran Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹19 Cr
QMar 2026
In Mar 2026, Kopran (KOPRAN) reported revenue ₹234 Cr and net profit ₹19 Cr — revenue +33.0% YoY. Also explore KOPRAN price movement history to track price trends across different timeframes.
KOPRAN Quarterly Results — Revenue, Profit & EPS Highlights
Kopran latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit KOPRAN screener.
- Revenue of ₹234 Cr in Mar 2026 (+98.3% vs Sept 2025, +33.0% vs Mar 2025)
- Net Profit of ₹19 Cr in Mar 2026 (+290.0% vs Sept 2025, +90.0% vs Mar 2025)
- EBITDA of ₹33 Cr in Mar 2026 (+760.0% vs Sept 2025)
- Operating Margin of 14.0% in Mar 2026 (+18.0pp vs Sept 2025)
- Earnings Per Share of ₹3.91 in Mar 2026 (+289.8% vs Sept 2025)
Kopran Quarterly Results — Revenue, EBITDA, Net Profit & EPS
KOPRAN quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 234 | 118 | 176 | 138 | 194 | 98.3% | 33.0% |
| Net Profit (₹ Cr) | 19 | -10 | 10 | 7 | 9 | - | - |
| EBITDA (₹ Cr) | 33 | -5 | 20 | 17 | 18 | - | - |
| EPS (₹) | 3.91 | -2.06 | 2.00 | 1.54 | 1.93 | - | - |
| Operating Margin (%) | 14.0% | -4.0% | 10.0% | 10.0% | 9.0% | - | - |
KOPRAN Share Price Trend — 1-Year Movement Across Quarterly Results
Kopran 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse KOPRAN financial statements for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Jun 2025
138
Mar 2025
176
Sept 2025
118
Mar 2026
234
Net Profit Trend (₹ Cr)
Jun 2025
7
Mar 2025
10
Sept 2025
-10
Mar 2026
19
Operating Margin Trend (%)
Jun 2025
10.0%
Mar 2025
10.0%
Sept 2025
-4.0%
Mar 2026
14.0%
KOPRAN vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Kopran latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores